Prostate TRITON3 (CO-338-063) A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency. Paris
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris
Sein métastatique RH+ EMERALD ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL Paris, Saint-Cloud
Sein métastatique RH+ TROPICS 02 (IMMU132-09) Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus;Treatment of Physician's Choice (TPC) in subjects with Hormonal;Receptor-Positive (HR+) Human Epidermal Growth Factor;Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC);who have failed at least two prior chemotherapy regimens Paris
Sein métastatique RH+ HerSeq (PUMA-NER-9501) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for;Enrollment into Clinical Research Studies of Neratinib Paris, Saint-Cloud
Sein métastatique RH+ PALATINE - UC-0140/1814 ADVANCED BREAST CANCER: THERAPY INTEGRATING LOCOREGIONAL TREATMENT IN DE NOVO,;TREATMENT NAIVE, STAGE IV ER+, HER2- BREAST CANCER PATIENTS RECEIVING LETROZOLE AND;PALBOCICLIB Paris, Saint-Cloud
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
Sein métastatique RH+ SERENA-2 (D8530C00002) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase;2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus;Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast;Cancer Paris FRANCOIS-CLEMENT BIDARD
Sein métastatique RH+ ESTROTIMP Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP) Paris, Saint-Cloud
Sein métastatique RH+ CT7001_003 (SUMIT ELA) A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer. Saint-Cloud FRANCOIS-CLEMENT BIDARD